[Prognostic factors in chronic lymphocytic leukaemia: contribution of recent biological markers].
Chronic lymphocytic leukemia (CLL) is the most common lymphoid hemopathy in elderly. Diagnosis of CLL is easily made with a full blood count and immunophenotyping, but there is an heterogeneity in clinical evolution. Until now, scheduling of treatment is based on Rai or Binet staging systems. These staging systems can not distinguish patients with a rapid evolution and thus who will need an earlier treatment. In order to detect these patients, it is useful to have some relevant markers to predict disease evolution. This article reviews recent biologic markers that can be used to evaluate long term prognosis of CLL patients.
Evrard
S
S
Service d'hématologie biologique, Hôpital européen Georges Pompidou, Paris.
Gaussem
P
P
Helley
D
D
Darnige
L
L
D014408:Biomarkers, Tumor / Q000096:biosynthesis* / Q000235:genetics*; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000235:genetics* / Q000378:metabolism*; D011379:Prognosis
D014408:Biomarkers, Tumor